Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

SCREEN Yourself for Cancer

4. november 2026 oppdatert av: Jennifer L. Moss, PhD, Milton S. Hershey Medical Center

SCREEN Yourself for Cancer (Self-Collection Research Examining Engagement and Navigation)

This randomized controlled trial will evaluate whether evidence-based self-sampling tools improve the cancer screening process among underscreened patients. Participants who are eligible but out-of-date for colorectal cancer screening, cervical cancer screening, or both will be randomized to either usual practice or an intervention that includes mailed self-sampling tools for the appropriate cancer screening test. Primary outcomes include screening initiation (within 12 months of enrollment) and screening completion (within 18 months of enrollment), for each cancer type. Secondary outcomes include repeat screening adherence and receipt of diagnostic resolution following abnormal screening results.

Studieoversikt

Detaljert beskrivelse

In the US, tens of thousands of people die from screen-preventable cancers each year. Failures occur across the entire cancer screening process, from screening initiation, to screening completion (i.e., receipt of a normal screening result or diagnostic resolution after an abnormal result), to repeat screening. Providing patients with self-sampling tools can improve these outcomes. These self-sampling tools (fecal immunochemical test [FIT] for colorectal cancer [CRC] screening and self-collected human papillomavirus [HPV] test for cervical cancer screening) enable patients to collect a sample at home and send it to a lab for testing. These tests are highly accurate and acceptable but not well-integrated into clinical care. Further, their impacts on screening completion and repeat screening are not well-studied. The proposed study is a rigorous, two-arm, parallel-groups randomized controlled trial to assess screening initiation, screening completion, and repeat screening among patients who are eligible but out-of-date with screening for CRC and/or cervical cancer. The study team will generate a census of patients in our healthcare system who meet study inclusion criteria and undertake stratified random selection to select patients for inclusion in the study. Patients will be randomized (1:1) to study arm: Usual practice arm, in which patients receive a letter informing them that they are out-of-date with cancer screening and encouraging them to make an appointment to get screened, and Self-sampling arm, in which patients receive self-sampling tool(s) and are encouraged to use it for cancer screening. As appropriate, patients will receive screening reminders, diagnostic resolution follow-up procedures, and 1-year repeat FIT for CRC screening. The study team will collect data from electronic health records and surveys. The study Aims are as follows:

Aim 1: Investigate between-arms differences in screening initiation. Aim 2: Examine between-arms differences in downstream screening outcomes. Aim 3: Identify mediators and moderators that impact the cancer screening process.

The recruitment goal for this study is 852 patients, including 542 who are eligible but out-of-date for CRC screening; 110 who are eligible but out-of-date for cervical cancer screening; and 200 who are eligible but out-of-date for both screenings. This sample will support rigorous, well-powered analyses of our Aims and hypotheses, using bivariate and multivariable analyses (including mediation and moderation analysis). This study will demonstrate the impact of self-sampling tools for the entire cancer screening process, which has significant implications for clinical care, public health, and behavioral research. The findings from the proposed study will support our long-term goal of identifying strategies to increase participation in the cancer screening process and to reduce screen-preventable cancer mortality in the US.

Studietype

Intervensjonell

Registrering (Antatt)

852

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

30 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • active patient at Penn State Health Department of Family and Community Medicine
  • patients eligible but out-of-date for routine colorectal cancer screening and/or routine cervical cancer screening
  • able to read and write in English, Spanish, or Nepali

Exclusion Criteria:

  • patients ineligible for routine colorectal and/or cervical cancer screening
  • patients up-to-date on routine colorectal and/or cervical cancer screening (as applicable)
  • not able to read and write in English, Spanish, or Nepali

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Screening
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Usual Practice

Participants will receive standard health system outreach (i.e., mailed reminders) encouraging completion of recommended colorectal and/or cervical cancer screening through routine clinical care pathways.

Routine mailed reminders and health system communication encouraging completion of guideline-recommended cancer screening.

Eksperimentell: Self-sampling arm

Participants will receive a package containing self-sampling tool(s) for colorectal and/or cervical cancer screening, encouraging them to complete screening with the self-sampling tool.

Education materials, instructions, and support documents accompanying mailed self-sampling kits.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Colorectal cancer screening initiation
Tidsramme: 12 months after baseline

The percentage of patients in each study arm who initiate colorectal cancer screening between baseline and 12-months follow-up, according to electronic health record data.

12 months after baseline
Cervical cancer screening initiation
Tidsramme: 12 months after baseline

The percentage of patients in each study arm who initiate cervical cancer screening between baseline and 12-months follow-up, according to electronic health record data.

12 months after baseline
Colorectal cancer screening completion
Tidsramme: 18 months after baseline

The percentage of patients in each study arm who complete colorectal cancer screening (i.e., receipt of a normal screening result or diagnostic resolution after an abnormal result) between baseline and 18-months follow-up, according to electronic health record data.

18 months after baseline
Cervical cancer screening completion
Tidsramme: 18 months after baseline

The percentage of patients in each study arm who complete cervical cancer screening (i.e., the receipt of a normal screening result or diagnostic resolution after an abnormal result) between baseline and 18-months follow-up, according to electronic health record data.

18 months after baseline

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Repeat colorectal cancer screening
Tidsramme: 24 months after baseline

Among patients who undergo colorectal cancer screening with FIT and receive normal test results, the percentage of patients who repeat colorectal cancer screening with FIT one year later, within 24 months of baseline, according to electronic health record data.

24 months after baseline
Receipt of diagnostic resolution after abnormal cancer screening results
Tidsramme: 6 months after initiating cancer screening

Among patients who undertake cancer screening and receive abnormal test results, the percentage of patients who receive diagnostic resolution procedures within 6 months of the test results, according to electronic health record data.

6 months after initiating cancer screening

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Jennifer L. Moss, PhD, Pennsylvania State University College of Medicine

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. mai 2027

Primær fullføring (Antatt)

31. desember 2029

Studiet fullført (Antatt)

31. desember 2030

Datoer for studieregistrering

Først innsendt

4. november 2026

Først innsendt som oppfylte QC-kriteriene

4. november 2026

Først lagt ut (Faktiske)

10. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

The study team will make scientific data and associated documentation publicly available through an institutional repository upon study completion. Deidentified participant-level data supporting published findings may be shared upon reasonable request, subject to institutional approvals and applicable data use agreements.

IPD-delingstidsramme

Beginning six months after final data collection, with no end date.

Tilgangskriterier for IPD-deling

Deidentified data and supporting information will be available to anyone through a publicly accessible, online data repository.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • ANALYTIC_CODE
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere